Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.21, $0.58 better than the analyst estimate of $3.63. Revenue for the quarter came in at $892.88 million versus the consensus estimate of $865.88 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2022 EPS of $16.00-$17.00, versus the consensus of $17.47.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.